Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dry Needling vs Botulinum Toxin Type A for Post-stroke Spasticity
NCT06296082Phase 3Recruiting
- Sponsor
- University of Antwerp
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, single-blind trial of botulinum toxin type A in Spasticity (2 arms), sponsored by University of Antwerp. Primary endpoint: Tonic Stretch Reflex Threshold at 19 weeks. Started Sep 2024; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT06296082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06296082.